CSMD: CONGRESS SMID GROWTH ETF
What this ETF is trying to do
The Congress SMID Growth ETF (CSMD) is designed to provide investors with exposure to growth-oriented companies. Based on its top holdings, it invests in a variety of businesses across different sectors, including healthcare, technology, and industrial companies.
What the numbers show
As of October 5, 2026, the share price of the ETF is $34.90.
When looking at how the price has changed over time, the data shows:
• Year-to-Date (YTD): The price return is 10.37%.
• One Year: The price return is 4.09%.
• Three Year: The price return is 47.15%.
The "price return" measures only the change in the share price. The "total return" includes both the price change and any distributions. For the one-year period, the total return is also 4.09%. For the three-year period, the total return is slightly higher at 47.74%.
To put the one-year price return into perspective, if you had invested $10,000 in this ETF roughly one year ago (when the estimated price was $33.53), your investment would be worth approximately $10,409 based on the price change alone.
Income and Distribution Explanation
Some investors look for ETFs that pay them regular cash, known as distributions. However, this ETF has a distribution yield of 0% and no distributions were detected over the last 12 months. This means it does not currently provide cash income to its shareholders.
NAV Erosion Explanation
"NAV erosion" happens when the actual value of the assets inside an ETF drops over time, which can lead to a falling share price. StockValueFinder uses an erosion-risk score to measure this.
CSMD has an erosion score of 94, which is labeled as "Stable / sideways" with "good" severity. Additionally, the severe erosion-risk flag is false, meaning the fund has not triggered a warning for substantial price deterioration.
Top Holdings
The ETF holds a total of 49 companies. Because the list is partial, we only see the largest holdings (as of October 7, 2026). The top five include:
• Halozyme Therapeutics Inc: 3.64%
• Repligen Corp: 3.51%
• nVent Electric PLC: 3.48%
• Curtiss-Wright Corp: 3.34%
• Valmont Industries Inc: 3.32%
Pros
• The ETF has shown strong growth over a three-year period.
• It has a "good" erosion-risk rating, suggesting price stability.
Cons
• It does not provide any cash income or distributions.
• The one-year price return is significantly lower than the three-year average.
Beginner Takeaway
The Congress SMID Growth ETF is focused on growth rather than income. While it has seen a large increase in price over the last three years, it does not pay dividends. Investors should remember that a high growth rate in the past does not guarantee the same results in the future.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | HALOZYME THERAPEUTICS INC | HALO | 3.64% |
| 2 | REPLIGEN CORP | RGEN | 3.51% |
| 3 | NVENT ELECTRIC PLC | NVT | 3.48% |
| 4 | CURTISS-WRIGHT CORP | CW | 3.34% |
| 5 | VALMONT INDUSTRIES INC | VMI | 3.32% |
| 6 | RUBRIK INC CLASS A SHARES | RBRK | 3.28% |
| 7 | CARPENTER TECHNOLOGY CORP | CRS | 3.14% |
| 8 | UFP TECHNOLOGIES INC | UFPT | 3.02% |
| 9 | MEDPACE HOLDINGS INC | MEDP | 2.81% |
| 10 | SAMSARA INC ORDINARY SHARES CLASS A | IOT | 2.76% |